T cells as therapeutic target in an acute myocardial infarction pig model (A2)

T cell-targeting immunotherapies improved wound healing and prolonged survival in mouse models of myocardial infarction (MI). In order to translate T cell-targeting therapies to human patients after MI we are now evaluating these successful immunotherapeutic approaches in a pig large animal MI model.


Recent studies from our groups and from others have revealed that T cell-targeting immunotherapies improve wound healing and survival in mouse models of MI. In order to translate these promising findings into novel therapies for humans we are now evaluating the immunotherapeutic approaches in the pig large animal model of MI.


We will evaluate novel T cell-targeting immunotherapies in pigs after MI as a critical step for clinical translation.


We will monitor cardiac function in pigs after balloon occlusion-induced MI using state-of-the-art methodologies and combine this with in-depth celluluar and humoral immunophenotyping including single cell RNAseq of heart-infiltrating T cells.

Significance and outlook

We expect that the evaluation of T cell-targeting therapies in the pig MI model will provide the basis for novel immunotherapies in patients after MI.


Portrait of PD Dr. med. Niklas Beyersdorf

PD Dr. med.
Niklas Beyersdorf

Leader of the CRC projects A2 and C5

+49 931-31-81527

Portraitfoto von Dr. med. Anna Frey

PD Dr. med.
Anna Frey

Leader of the CRC project A2

+49 9321 201-39927


Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Zentrum für Innere Medizin (ZIM), Oberdürrbacher Straße 6, Haus A3, 97080 Würzburg, Deutschland 

Deutsches Zentrum für Herzinsuffizienz Würzburg | Comprehensive Heart Failure Center | Am Schwarzenberg 15 | Haus A15 | 97078 Würzburg